SJ-3366 Sam Jin Pharmaceutical.
Sam Jin is investigating SJ-3366, a non-nucleoside reverse transcriptase inhibitor (NNRTI), for the potential treatment of HIV infection [302450]. As well as acting as an NNRTI, SJ-3366 also interferes with HIV-1 entry via an intermediate target formed after virus-cell attachment [341146], [363900]. As of June 1998, Sam Jin had been awarded a patent for SJ-3366 in South Africa, with applications pending in 22 other countries [302450].
Baba
Masanori
M
Center for Chronic Viral Diseases, Faculty of Medicine, Kagoshima University, Japan. baba@m.kufm.kagoshima-u.ac.jp
D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000378:metabolism*; D006801:Humans; D010330:Patents as Topic; D011744:Pyrimidinones / Q000494:pharmacology / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; C425105:SJ3366; D054303:HIV Reverse Transcriptase